研究

Kamigaichi A, Hamada A, Tsutani Y.

Segmentectomy for patients with early-stage pure-solid non-small cell lung cancer

Rafael Rosell,María González-Cao, Jordi Codony-Servat, Miguel Angel Molina-Vila,Clara Mayo de las Casas, Masaoki Ito

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer

Ito M, Miyata Y, Kushitani K, Ueda D, Takeshima Y, Okada M.

Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.

Pedraz-Valdunciel C, Ito M, Giannoukakos S, Giménez-Capitán A, Molina-Vila MA, Rosell R.

Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC

Ito M, Miyata Y, Okada M.

Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: A systematic review

Tomoshige K, Stuart WD, Fink-Baldauf IM, Ito M, Tsuchiya T, Nagayasu T, Yamatsuji T, Okada M, Fukazawa T, Guo M, Maeda Y.

FOXA2 with mutant KRAS drives invasive mucinous adenocarcinoma of the lung

Sanchez-Moral L, Paul T, Martori C, Font-Díaz J, Sanjurjo L, Aran G, Téllez É, Blanco J, Carrillo J, Ito M, Tuttolomondo M, Ditzel HJ, Fumagalli C, Tapia G, Sidorova J, Masnou H, Fernández-Sanmartín MA, Lozano JJ, Vilaplana C, Rodriguez-Cortés A, Armengol C, Valledor AF, Kremer L, Sarrias MR.

Macrophage CD5L is a target for cancer immunotherapy

Rosell R, González-Cao M, Ito M, Santarpia M, Aguilar A, Codony-Servat J.

The role of biomarkers in stage III non-small cell lung cancer

Rosell R, Mariacarmela Santarpia, Pedraz-Valdunciel C, Giuliana Ciappina, Andrés Aguilar, Giménez-Capitán A, Ito M, González-Cao M, Molina-Vila MA.

Liquid biopsy in detecting early non-small cell lung cancer

Miyoshi T, Ito H, Wakabayashi M, Hashimoto T, Sekino Y, Suzuki K, Tsuboi M, Moriya Y, Yoshino I, Isaka T, Hattori A, Mimae T, Isaka M, Maniwa T, Endo M, Yoshioka H, Nakagawa K, Nakajima R, Tsutani Y, Saji H, Okada M, Aokage K, Fukuda H, Watanabe SI.

Risk factors for loss of pulmonary function after wedge resection for peripheral ground-glass opacity dominant lung cancer.

Akira Hamada,Kazuhiro Kitajima,Kenichi Suda,Takamasa Koga, Junichi Soh, Hayato Kaida, Kimiteru Ito, Tetsuro Sekine, Kyoshiro Takegahara,
Hiromitsu Daisaki, Masaki Hashimoto, Yukihiro Yoshida, Takanobu Kabasawa, Takashi Yamasaki,Seiichi Hirota, Jitsuo Usuda, Kazunari Ishii, Tetsuya Mitsudomi,

Prognostic role of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography with an image-based harmonization technique: A multicenter retrospective study

Rafael Rosell,María González-Cao, Jordi Codony-Servat, Miguel Angel Molina-Vila,Clara Mayo de las Casas, Masaoki Ito

Acquired BRAF gene fusions in Osimertinib resistant
EGFR-mutant non-small cell lung cancer

Ito M, Miyata Y, Kushitani K, Ueda D, Takeshima Y, Okada M.

Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.

Kenichi Suda , Kazuko Sakai , Tatsuo Ohira ,Takaaki Chikugo ,Takao Satou , Jun Matsubayashi ,Toshitaka Nagao ,Norihiko Ikeda, Yasuhiro Tsutani , Tetsuya Mitsudomi ,and Kazuto Nishio,

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening

Yamamoto H, Soh J, Okumura N, Suzuki H, Nakata M, Fujiwara T, Gemba K, Sano I, Fujinaga T, Kataoka M, Terazaki Y, Fujimoto N, Kataoka K, Kosaka S, Yamashita M, Inokawa H, Inoue M, Nakamura H, Yamashita Y, Hotta K, Yoshioka H,

Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201

NobutakaKawamoto,TakahiroMimae,YasuhiroTsutani, AtsushiKamigaichi,NorifumiTsubokawa,YoshihiroMiyata,MorihitoOkada

Tumor distance from the mediastinum predicts N2 upstaging in clinical stage I lower-lobe non-small cell lung cancer

Fujiwara T, Shien K, Matsuura M, Soh J, Yamamoto H, Takao S, Maki Y, Ueno T, Sugimoto R, Suzawa K, Okazaki M, Tao H, Hayama M, Kataoka M, Sano Y, Inokawa H, Yamashita M, Kawamata O, Kataoka K, Toyooka S.

ASO Visual Abstract: EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery

Yoshimura A, Yamada T, Serizawa M, Uehara H, Tanimura K, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Shukuya T, Nishiyama A, Goto Y, Shiotsu S, Kunimasa K, Morimoto K, Katayama Y, Suda K, Mitsudomi T, Yano S, Kenmotsu H, Takahashi T, Takayama K

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib

Kagimoto A, Tsutani Y, Kushitani K, Kambara T, Mimae T, Miyata Y, Takeshima Y, Okada M.

Usefulness of serum S100A4 and positron-emission tomography on lung cancer accompanied by interstitial pneumonia.

Kawamoto N, Tsutani Y, Kamigaichi A, Ohsawa M, Mimae T, Miyata Y, Okada M.

Tumour location predicts occult N1 nodal metastasis in clinical stage I non-small-cell lung cancer.

Tsutani Y, Goldman JW, Dacic S, Yatabe Y, Majem M, Huang X, Chen A, van der Gronde T, He J.

Adjuvant osimertinib versus placebo in completely resected stage IA2-IA3 EGFR-mutated NSCLC: ADAURA2.

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N.

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer

Aokage K, Suzuki K, Saji H, Wakabayashi M, Kataoka T, Sekino Y, Fukuda H, Endo M, Hattori A, Mimae T, Miyoshi T, Isaka M, Yoshioka H, Nakajima R, Nakagawa K, Okami J, Ito H, Kuroda H, Tsuboi M, Okumura N, Takahama M, Ohde Y, Aoki T, Tsutani Y, Okada M, Watanabe SI; Japan Clinical Oncology Group.

Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.